Bharat Parenterals shareholding pattern

BPLPHARMA

1100.55

0.00 (0.00%)
Last updated on 20 Feb, 2026 | 15:29 IST
alert_iconwatchlist_icon
BUYSELL
Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Bharat Parenterals Shareholding Pattern

  • 2018-19
  • 2019-20
  • 2020-21
  • 2021-22
  • 2022-23
  • 2023-24
  • 2024-25
  • 2025-26
Total Promoters
Segment
Percent

Total Promoters

67.19%

Mutual Fund

0%

Insurance

0%

Foreign Institutional Investors

0.11%

Domestic Institutional Investors

0.54%

Retail

32.15%

Others

0.01%

Total Promoters
MAR '25
67.2%
JUN '25
67.19%
SEP '25
67.19%
DEC '25
67.19%

Summary

For Year 2025-26, Bharat Parenterals reports the following shareholding: Total Promoters at 67.19%, Mutual Fund at 0%, Insurance at 0%, Foreign Institutional Investors at 0.11%, Domestic Institutional Investors at 0.54%, and Retail at 32.15%. This breakdown provides a quick snapshot of ownership distribution for Bharat Parenterals in 2025-26.

Bharat Parenterals FAQs

As of 02-2026, the promoter shareholding in Bharat Parenterals stands at 67.19% of the company's total shares. Promoter shareholding represents the ownership stake held by the company's founding members, management, or controlling entities, having a significant influence on the company's strategic direction and operations.

The FII and DII shareholding of Bharat Parenterals is 0.11% and 0.54% respectively.

The retail shareholding of the Bharat Parenterals is 32.15%.

Changes in shareholding patterns of Bharat Parenterals can result from stock market transactions, issuance of new shares, buybacks, mergers, acquisitions, or changes in promoter holdings.

Shareholding patterns of Bharat Parenterals are updated quarterly as mandated by regulatory authorities and may also be disclosed during significant corporate events.

The latest shareholding pattern is available on stock exchanges (e.g., NSE, BSE) and the company's official website under investor relations.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost